A Roche of la Grippe: India’s Natco and Alvogen launch Tamiflu generic in US

By Dani Bancroft contact

- Last updated on GMT

Image: Natco Pharma
Image: Natco Pharma

Related tags: Oseltamivir, Influenza

Natco Pharma and partner Alvogen have launched the “first generic equivalent” of Roche’s Tamiflu (oseltamivir phosphate) in the US.

The US FDA approved India based Natco Pharma and its US partner Alvogen’s application for a generic of Tamiflu in August.

Alvogen—a CMO with more than 350 generic products on the market—told Reuters​ it expected “the cheaper product to save the US healthcare system over $500M in the upcoming flu season.”

Tamiflu has previously faced criticism after a 2014 Cochrane review​ reported little evidence of the drug’s efficacy in reducing viral spread, the number of complications and hospitalisations of patients with influenza.


Oseltamivir phosphate is an oral neuraminidase inhibitor invented by Gilead Science Inc., licensed out to Roche as Tamiflu in 1996.

In 2011, Natco first challenged​ Gilead’s patent of Tamiflu, over claims it was invalid. A settlement was made last December, with Natco proceeding to go ahead with development of its 30mg, 50mg and 75mg of oseltamivir phosphate capsules.

But Natco and Alvogen are not alone in their pursuit of a Tamiflu generic.

Cipla Ltd. marketed Antiflu back in 2011, which contains the same API as Tamiflu—oseltamivir phosphate—in a capsule and syrup formulation.

Roche granted Hetero Drugs​ in India a sublicense to manufacture oseltamivir in 2006.

Natco and Alvogen did not respond to requests for further information.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more